New guideline updates care for central precocious puberty

The Endocrine Society has released a new clinical practice guideline on the diagnosis and treatment of central precocious puberty (CPP), recommending a more individualized approach that may reduce unnecessary testing and treatment for some children while maintaining appropriate care for those at risk of adverse outcomes. The guideline was published in The Journal of Clinical Endocrinology & Metabolism and was developed with support from multiple pediatric and endocrine organizations, including the American Academy of Pediatrics.^1,2

CPP occurs when activation of the hypothalamic-pituitary-gonadal axis begins earlier than expected, resulting in the development of secondary sexual characteristics before age 8 years in girls and before age 9 years in boys. The condition has been associated with reduced adult height potential, psychosocial challenges, and increased risks of cardiometabolic disease and certain cancers later in life.

“Children who start puberty earlier than usual should be carefully evaluated so they receive the right care at the right time—without unnecessary tests or treatment,” said guideline writing group chair Ana Claudia Latronico, MD, PhD, of the University of São Paulo in Brazil. “The Endocrine Society’s guideline gives clinicians evidence-based suggestions to identify central precocious puberty, understand its causes, and decide when and what treatment is appropriate.”

Which children may benefit from observation before testing?

One of the guideline's most notable recommendations is a period of observation before initiating extensive diagnostic testing in selected girls with early pubertal development. The panel suggests monitoring girls who develop breast tissue between the ages of 7 and 8 years with physical examinations every 4 to 6 months rather than immediately pursuing laboratory studies or imaging. The recommendation is based on evidence that many girls with slowly progressive puberty ultimately achieve normal adult height without intervention.

The guideline also recommends a 4- to 6-month observation period for girls younger than 7 years with initial breast development to help distinguish slowly progressive puberty from more rapidly advancing disease. Diagnostic evaluation remains appropriate for children with accelerated growth, rapid pubertal progression, or neurologic symptoms.

“Some subgroups of children may not need the same level of testing or treatment. For example, older girls with slowly progressing precocious puberty often have normal adult height without intervention,” said guideline co-chair Stephanie Roberts, MD, of Boston Children’s Hospital. “We give clinicians suggestions that avoid unnecessary or invasive testing and treatment, such as sometimes initially using a period of observation by their health care provider, using simpler testing methods, and individualizing treatment when indicated.”

How do the recommendations change diagnostic evaluation?

The guideline recommends using a basal luteinizing hormone (LH) measurement obtained with an ultrasensitive assay as the initial hormonal test rather than routinely performing gonadotropin-releasing hormone stimulation testing in all patients. According to the authors, this approach may simplify evaluation while maintaining diagnostic accuracy.

The panel also advises against routinely obtaining brain magnetic resonance imaging in girls aged 6 to 8 years and boys aged 8 to 9 years who have CPP but no neurologic symptoms. The recommendation reflects evidence suggesting a relatively low prevalence of significant intracranial pathology in these groups. Similarly, routine genetic testing is not recommended, although testing may be considered in children with a family history of CPP through shared decision-making.

What does the guideline recommend for treatment?

For many children with confirmed CPP, the guideline supports treatment with gonadotropin-releasing hormone agonists, which suppress premature pubertal progression and may improve adult height outcomes. However, the panel noted that not all patients are expected to derive the same benefit, particularly older girls with slowly progressive disease.

When long-term therapy is anticipated, the guideline recommends initiating treatment with longer-acting formulations rather than starting with monthly preparations and later transitioning. The authors also advise against routine use of adjunctive growth hormone therapy and recommend clinical monitoring over routine laboratory monitoring during treatment unless treatment failure is suspected.

The guideline further recommends discontinuing therapy by early adolescence, generally around ages 10 to 11 years in girls and 11 to 12 years in boys, while recognizing that decisions should be individualized based on growth, psychosocial considerations, and other clinical factors.

The authors noted that many recommendations were based on limited evidence and highlighted the need for additional research. Nevertheless, they emphasized that the overarching goal is to provide diagnostic and treatment strategies that maximize clinical benefit while minimizing unnecessary interventions for children and families facing CPP.

References

1. Latronico AC, Roberts SA, Alonzo M, et al. Central precocious puberty: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Published online June 13, 2026. doi:10.1210/clinem/dgag168

2. Endocrine Society. Not All Children with Early Puberty Need the Same Level of Testing or Treatment. Newswise. June 13, 2026. Accessed June 23, 2026. https://www.newswise.com/articles/not-all-children-with-early-puberty-need-the-same-level-of-testing-or-treatment